Related Experiment Videos
[Aggressive lymphomas]
1Service d'hématologie clinique Hôpital Henri-Mondor, 94010 Créteil. corinne.haioun@hmn.ap-hop-paris.fr
La Revue Du Praticien
|June 18, 2002
Summary
This review covers aggressive lymphoma treatments, detailing chemotherapy regimens and prognostic factors. It highlights first-line options, high-dose therapy, salvage treatments, and the impact of CD20 monoclonal antibody immunotherapy.
Area of Science:
- Oncology
- Hematology
Context:
- Aggressive lymphomas represent a significant challenge in hematologic malignancies.
- Treatment decisions are guided by prognostic factors and disease stage.
Purpose:
- To review current and emerging treatment strategies for aggressive lymphomas.
- To outline the role of chemotherapy, high-dose therapy, and immunotherapy.
Summary:
- Chemotherapy regimens and prognostic factors are described for localized and advanced aggressive lymphomas.
- High-dose therapy with hematopoietic support and salvage treatments for treatment failures are discussed.
- The significant impact of CD20 monoclonal antibody immunotherapy on treatment outcomes is highlighted.
Impact:
- Provides a comprehensive overview of aggressive lymphoma management.
- Informs clinical decision-making for oncologists and hematologists.
- Highlights the evolving landscape of lymphoma treatment with immunotherapy.